Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CDC ACIP Unanimously Votes to Provisionally Recommend Merck?s VAXNEUVANCE?

10/20/2021 | 07:07pm EST

Merck & Co., Inc. announced the U.S. Centers for Disease Control and Prevention?s (CDC?s) Advisory Committee on Immunization Practices (ACIP) unanimously voted in favor of updates to pneumococcal vaccination recommendations for adults 65 years and older, and for adults ages 19 to 64 with certain underlying medical conditions (e.g., chronic conditions such as diabetes, chronic heart disease, chronic lung disease, or chronic liver disease, as well as HIV, an immunocompromising condition) or other disease risk factors (e.g., smoking, alcoholism). In both groups, the ACIP voted to provisionally recommend vaccination either with a sequential regimen of VAXNEUVANCEfollowed by PNEUMOVAX, or with a single dose of 20-valent pneumococcal conjugate vaccine. These updates would apply to adults who have not previously received a pneumococcal conjugate vaccine or whose previous pneumococcal vaccination history is unknown. PNEUMOVAX 23 is indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F), in persons 50 years of age or older and persons aged =2 years who are at increased risk for pneumococcal disease; PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine. PNEUMOVAX 23 is contraindicated in individuals with a history of a hypersensitivity reaction to any component of PNEUMOVAX 23.


ę S&P Capital IQ 2021
All news about MERCK & CO., INC.
05:19aWells Fargo Starts Merck at Overweight With $90 Price Target
MT
12/08UK Initiates Study of COVID-19 Therapies from Merck & Co., Roche-Regeneron
MT
12/08GLOBAL MARKETS LIVE : Airbus, BP, Merck, Pfizer, Meta...
12/08Merck Prices $8 Billion Senior Notes Offering
MT
12/08Lytix Biopharma Starts Treatment of First Patient in Mid-Stage Trial for Tumor Drug
MT
12/07Merck & Co. Allocates Additional $150 Million For Global Maternal Health Program
MT
12/07Merck Prices $8.0 Billion Debt Offering
BU
12/07Merck Announces Five-Part US Dollar Issuance With Maturities From 5-40 Years
MT
12/07Guggenheim Downgrades Merck to Neutral From Buy
MT
12/07Merck Pledges Additional $150 Million to End Maternal Mortality Inequities
MT
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 562 M - -
Net income 2021 12 218 M - -
Net Debt 2021 20 562 M - -
P/E ratio 2021 15,2x
Yield 2021 3,55%
Capitalization 185 B 185 B -
EV / Sales 2021 4,23x
EV / Sales 2022 3,54x
Nbr of Employees 73 500
Free-Float 70,5%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 73,21 $
Average target price 94,85 $
Spread / Average Target 29,6%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-10.50%184 924
JOHNSON & JOHNSON4.42%432 641
ROCHE HOLDING AG20.68%329 493
PFIZER, INC.39.64%288 501
NOVO NORDISK A/S73.12%256 630
ELI LILLY AND COMPANY45.17%221 499